COMMUNIQUÉS West-GlobeNewswire

Chembio Receives $8.5 Million Commitment from Bio-Manguinhos to Purchase Components for Production of DPP® Assays in Brazil during 2018
05/12/2017
MEDFORD, N.Y., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI ), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that it has received an $8.5 million [...]
Mateon Announces Preclinical Data Indicating Enhanced Tumor Immune Response of CA4P with Checkpoint Inhibitor
05/12/2017
Addition of CA4P simultaneously reduces tumor volume and increases tumor white blood cells, T Cells and cytotoxic T Cells compared to anti-CTLA-4 monotherapy Preliminary data suggest immuno-oncology applications for [...]
CV Sciences, Inc. Repays Installment Obligation on Convertible Debt
05/12/2017
LAS VEGAS, Dec. 05, 2017 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our” or “we”) announced today that it has paid the December 2017 installment obligation under its March 1, 2017 [...]
Novan Announces First Patient Dosed in Phase 1b Atopic Dermatitis Trial with SB414
05/12/2017
MORRISVILLE, N.C., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ: NOVN ) today announced that the first patient has been dosed in the Company's Phase 1b clinical trial to evaluate [...]
Antibacterial Benefits of PEKK for Orthopedic Applications Detailed in Study of 3D-Printed OsteoFab® Structures
05/12/2017
SOUTH WINDSOR, Conn., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Oxford Performance Materials, Inc. (OPM), a leader in advanced materials science and high performance additive manufacturing (HPAM™), today announced the results [...]
Fortress Biotech Forms Subsidiary Tamid Bio to Develop Novel AAV Gene Therapies in Orphan Diseases With Unmet Medical Needs
05/12/2017
NEW YORK, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO ) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology [...]
Sarepta Therapeutics Elects Biopharmaceutical Veteran, Michael W. Bonney, to its Board of Directors
05/12/2017
CAMBRIDGE, Mass., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT ), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to [...]
100% of Prostate Cancer Patients Completing 31-Week Post-Therapy Exam After Treatment with OncBioMune Immunotherapy Show No Disease Progression
05/12/2017
BATON ROUGE, La., Dec. 05, 2017 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of a proprietary [...]
Galectin Therapeutics Announces Results from Phase 2b NASH-CX Trial
05/12/2017
Statistically significant and clinically meaningful effects observed in NASH cirrhosis patients without esophageal varices treated with GR-MD-02 Conference Call at 8:30 A.M. ET to Present Top Line Trial Results NORCROSS [...]
BIOLIFE4D Comments on New Guidelines for High Blood Pressure in Adults
05/12/2017
CHICAGO, Dec. 05, 2017 (GLOBE NEWSWIRE) -- BIOLIFE4D , a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today commented on a new report from the American [...]
Tyme Provides Update on At-The-Market Financing Activity
05/12/2017
NEW YORK, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (Nasdaq: TYME ), a clinical-stage biotechnology company developing cancer therapeutics, announced it has raised gross proceeds of approximately $5.0 [...]
Ovid Therapeutics Announces TAK-935/OV935 Has Received Orphan Drug Designation from U.S. FDA for Treatment of Dravet Syndrome
05/12/2017
NEW YORK, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID ), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today [...]
CRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Medicine for β-Thalassemia and Sickle Cell Disease, at the ASH Annual Meeting
05/12/2017
ZUG, Switzerland and CAMBRIDGE, Mass., Dec. 05, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP ) today announced that Dr. Bill Lundberg, Chief Scientific Officer of CRISPR, is scheduled to present new data [...]
Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101 at the American Association for Cancer Research Prostate Cancer Meeting
05/12/2017
SAN DIEGO, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, today presented [...]
Favorable Results from a Multi-Center Analysis of Delcath PHP Therapy to be Published in Journal of Surgical Oncology
05/12/2017
NEW YORK, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that results of a multi- [...]
Updated Results from Phase I Study of CB-839 in Combination with Paclitaxel in Patients with Triple Negative Breast Cancer to be Presented at the 2017 San Antonio Breast Cancer Symposium
05/12/2017
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA ), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs [...]
Intellipharmaceutics Announces Receipt of Nasdaq Notice
05/12/2017
TORONTO, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq: IPCI ) (TSX: IPCI ) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, [...]
Actinium Pharmaceuticals Unveils Actimab-MDS and Planned Phase 2 Trial in Myelodysplastic Syndromes Targeted at Patients with High-Risk p53+ Genetic Mutations
05/12/2017
Phase 2 clinical trial planned for 2018, Actimab-MDS intended to be a bridge to a bone marrow transplant, the only curative treatment option for patients with myelodysplastic syndrome Trial principal investigator, Dr. [...]
Spark Therapeutics Announces Multiple Presentations on Updated Hemophilia A and Hemophilia B Phase 1/2 Clinical Trials at 59th American Society of Hematology Annual Meeting and Exposition
05/12/2017
PHILADELPHIA, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE ), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that Lindsey A. [...]

Pages